Clinical Trial Update: A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 [Phase 1, Phase 2]

View source ↗

Summary

A long-term follow-up study of participants from a previous Phase I/II trial in malignant melanoma has terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• IMM 101

Snippet

Sponsor: Immodulon Therapeutics Ltd | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-05-24